[
  {
    "ts": null,
    "headline": "BSX's Neuromodulation Arm Sees Growth: Q1 Highlights",
    "summary": "Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.",
    "url": "https://finnhub.io/api/news?id=d84a0e61b77c4d02feea214ce00b9da2b00b119d7cef40d6f5f7f08b132c4394",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750252320,
      "headline": "BSX's Neuromodulation Arm Sees Growth: Q1 Highlights",
      "id": 135370973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.",
      "url": "https://finnhub.io/api/news?id=d84a0e61b77c4d02feea214ce00b9da2b00b119d7cef40d6f5f7f08b132c4394"
    }
  },
  {
    "ts": null,
    "headline": "ISRG vs BSX: Which Medical Device Stock Has More Room to Run?",
    "summary": "Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.",
    "url": "https://finnhub.io/api/news?id=fbf0e84a8c474b12704b0a9e1e745a85959084a291145b14cb2d53944f85ec93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750251300,
      "headline": "ISRG vs BSX: Which Medical Device Stock Has More Room to Run?",
      "id": 135358808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.",
      "url": "https://finnhub.io/api/news?id=fbf0e84a8c474b12704b0a9e1e745a85959084a291145b14cb2d53944f85ec93"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific’s Q1 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Boston Scientific’s first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth,",
    "url": "https://finnhub.io/api/news?id=2310a507ff38dbd40a7b303937bd0d492719c97cd6cb47472a97e1ddcfbd8ad8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750242360,
      "headline": "Boston Scientific’s Q1 Earnings Call: Our Top 5 Analyst Questions",
      "id": 135353680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific’s first quarter results were met with a positive market reaction following revenue and profit that surpassed Wall Street expectations. Management credited robust growth in its cardiology portfolio and the successful execution of a category leadership strategy spanning electrophysiology, WATCHMAN, and interventional cardiology products. CEO Michael Mahoney highlighted that double-digit expansion in the U.S. and momentum in Europe and Japan helped drive operational sales growth,",
      "url": "https://finnhub.io/api/news?id=2310a507ff38dbd40a7b303937bd0d492719c97cd6cb47472a97e1ddcfbd8ad8"
    }
  }
]